Slang Archives - Page 2 of 2 - Green Market Report

Debra BorchardtOctober 2, 2019


Vape products, once considered the rising stars of the legal cannabis marketplace have struggled under the weight of the vaping crisis. Massachusetts banned all vape products for four months in order to err on the side of caution while the issue is investigated. Around the middle of August, vape product sales began dropping according to data from Headset, however, it seems the group may be slowly recovering. The following table was provided by Headset.

Sales in Nevada and Washington both began to pick back up, while California seems to have stabilized. Most consumers are learning that the issues with vapes stemmed from products purchased outside the regulated channels. 

A report from the CDC (Center for Disease Control) stated, “In addition, the report from Illinois and Wisconsin showed that nearly all THC-containing products reported were packaged, prefilled cartridges that were primarily acquired from informal sources such as friends, family members, illicit dealers, or off the street.”

It seems illicit market and unregulated vape producers were using thickening agents like Vitamin E with disastrous results. The industry, in general, has suggested that regulation will solve this issue and many are trying to convince the consumer that they can trust a regulated brand.

“The widely publicized public health issue relating to the use of liquid vapes is something that SLANG takes extremely seriously,” said SLANG Worldwide (OTC: SLGWF) CEO Peter Miller. “We encourage investigation and research into the causes of this issue and hope that our collective understanding of the results leads to more thorough and effective regulation of the industry.”

SLANG said it is not aware of any of its products being identified as a contributor to any of the recent illnesses associated with vaping technology. SLANG is not currently operating in Massachusetts and had postponed plans to enter that state. It doesn’t expect to be adversely impacted by Massachusetts’ temporary ban on vaping products.

1933 Industries (CSE: TGIF) (OTCQX: TGIFF) said, “All our branded THC and CBD vape products do not contain vitamin E acetate, vegetable glycerin, or propylene glycol. All our products are made with ingredients that are known to be safe for consumers. All packaging contains our product ingredients, which are also listed on our website. Each and every product is third-party lab tested, and the results can be tracked via a QR code.”

Testing Boom

Of course, in order to be sure testing is the best way to go and this crisis could present an opportunity for the lab group to capitalize. CannaSafe, California’s leading accredited cannabis testing laboratory said it will expand contaminant testing to Vitamin E additives, in response to ongoing concerns around consumer vaping safety. CannaSafe is the first laboratory to offer this service and will also provide testing for additional additives including medium-chain triglycerides, vegetable glycerin, and propylene glycol in the coming weeks.

“Trusted cannabis companies are taking it upon themselves to impose high-quality standards on consumer products, and we are ready to work with any business that wants to show customers that their products are free of toxic additives,” said Aaron Riley, CEO of CannaSafe. “We also urge brands and retailers to share test results with their customers as a gesture of good faith.”

Modern wellness company, dosist, is the first brand to voluntarily undergo Vitamin E testing with CannaSafe. Other brands that will utilize Cannasafe’s testing technology include Orchid Essentials, Select, Heavy Hitters, Stiiizy, King Pen, Lowell Herb Co., Pure Vape, Tikun, and Raw Garden. The Vitamin E test is available to brands and manufacturers across the state for an additional $225.


Debra BorchardtAugust 28, 2019


SLANG Worldwide Inc. (CNSX: SLNG) delivered its financial results in Canadian dollars for the second quarter ending June 30, 2019, with revenue increased sequentially by 44% to $7.2 million and a big jump over last year’s $440,000 for the same time period. More importantly, Slang reported a net income of $17.5 million in the quarter versus a net loss of $13 million for the same time period in 2018. An even bigger accomplishment sequentially with a net loss of $16.1 million in the first quarter.

Revenue Plans Revised Down

Still, the company revised its outlook downward from its previously estimated $130-$160 million to a more conservative $70-$100 million.  Canada’s vape business was pushed back from October to mid-December, significantly affecting Slang’s vape plans. The company also said that it has decided to focus on growth in mature markets where our brands are currently performing well, versus Massachusetts and Michigan which have been growing much more slowly.

“These markets have been developing at a slower pace than anticipated and are currently facing supply constraints. While management believes these markets offer significant longer-term opportunities for the SLANG brands, further investment in growth initiatives in the current environment would put pressure on margins and profitability.” The company also said it plans to delay the launch of new products.

“We saw significant momentum across our business and delivered strong growth in revenue and unit sales in Q2 over the previous three months. Through each deal and initiative we announced in the quarter, we adhered to the capital-light model that we believe delivers the best value for our shareholders,” said SLANG CEO Peter Miller. “Global cultural, political and commercial tailwinds represent a huge organic growth opportunity for our brands. We will responsibly scale into this opportunity, continuing to focus on building a great team and the right assets to efficiently and competitively deliver our products to market. We continue to see strong organic growth opportunities for the remainder of 2019 and beyond, and remain optimistic about the outlook for the business.”

The company noted that its current increase in revenue reflected the inclusion of a full quarter of operations, sequential growth in Nevada and Oregon, positive changes in product mix, the initiation of sales of the Firefly 2+ vaporizer as well as the Company’s first sales in Florida and Puerto Rico.

Additional highlights from the company were as follows:

  • .1 million branded units sold — Branded unit volumes have increased by 16% over Q1 2019 following the start of sales in Florida, and growth in Nevada and Oregon.
  • Nearly 74 million branded servings (average of 800,000+ servings per day) — Branded servings grew by 45% in the quarter versus Q1 2019. Percentage growth in branded servings significantly outpaced growth in branded units as product mix shifted towards higher volume form factors.
  • 2,600+ retail stores across 12 states selling SLANG’s branded products — SLANG commenced sales in Florida during the quarter and announced several agreements to initiate sales in additional high-quality cannabis markets. The Company will continue to leverage its extensive distribution network and corporate development activity to grow its business through the balance of 2019.


Debra BorchardtMay 24, 2019



SLANG Worldwide Inc. (CSE:SLNG) elected to exercise its right under the warrant indenture governing the common share purchase warrants of the company issued on July 23, 2018, to accelerate the expiry date of the Warrants. Slang may accelerate the expiry date of the Warrants if, at any time prior to July 21, 2020, the closing trading price of the common shares of the company on the Canadian Securities Exchange exceeds $1.75 for a period of at least 20 consecutive trading days. As of the close of markets on May 23, 2019, the closing trading price of the Common Shares on the CSE exceeded $1.75 per Common Share for more than 20 consecutive trading days.

As of May 23, 2019, a total of 9,101,927 of the 13,436,005 originally issued Warrants had yet to be exercised. Each Warrant is exercisable to acquire one Common Share at an exercise price of $1.15. Consequently, if all Warrants are exercised, proceeds to the Company will total $10,467,216.05.


The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF)  announced that the Nasdaq Stock Market has approved the Company’s application to have its common shares listed on the Nasdaq Capital Market. A trading date will be announced once the company’s Form 40-F registration statement becomes effective with the SEC. The common shares will be listed on the Nasdaq under the symbol “FLWR”. The Company’s common shares listed on the TSX Venture Exchange will continue to trade under the symbol FLWR.

Green Growth Brands

 Green Growth Brands, Inc. (CSE: GGB) (OTCQB: GGBXF) approved the grant of an aggregate of 595,000 restricted share units under the company’s equity incentive plan to certain of its employees. The RSUs will be granted to the RSU Recipients as compensation for their services to the company and as an incentive mechanism to foster the interest of such persons in the long-term success of the company.

True Leaf Brands

True Leaf Medicine International Ltd. (CSE: MJ) (OTCQX: TRLFF)  announced today that, effective immediately, the Company is officially changing its corporate name to True Leaf Brands Inc. 

Video StaffMay 15, 2019


Tim Seymour:                    It’s really exciting to be here with Peter, who as you heard if you didn’t know Peter’s background. I mean this is a gentleman who’s been a pioneer in an industry that pioneering 10 years ago or even in 2014 was a lot more difficult than it is today. We had a chance to catch up in the green room and one of the topics just was a change in perception and how that’s really, really changed the playing field.

But before we get into that, I actually think it’d be very helpful, Peter, for the audience to hear a little about how you started out 10 years ago, because then I want to talk about Mettrum was one of the first real big transactions in the industry that inspired so many other operators to not only seek out major partners, but get going. I want to hear about that.

We’re here to talk about SLANG, because it’s been an exciting six months for your company. Start us just a little bit at the beginning of how you got here.

Peter Miller:                       Ten years ago cannabis was still this super illegal product almost everywhere. Probably similar us to today, but it was highly stigmatized, and obviously there wasn’t an industry. Canada had this grow for yourself model that was the result of a series of lawsuits where people basically said, “If Canadians have a human right to medicine and cannabis is medicine, then it’s a human right that we should be able to access cannabis.” That was a successful argument which led to the government trying to figure out how people would access cannabis. There was an RFP, a company that became Cannimed won that RFP, which is now Aurora, but ultimately it was new. They weren’t producing cannabis very successfully. There was another lawsuit, and the patients said, “We should be able to grow for yourself because not only can we not afford this, but it’s no good.” And that was successful.

Then there was this proliferation of quasi … well illegal if you were selling to anyone other than the three designated people you were allowed to grow for, and that created this highly distributed gray/black market in Canada. Fast forward to 2010, 2011, the governments trying to figure out how this should all be handled, and we had quite a conservative leader in power who wanted to just get rid of it, and his idea for getting rid of it was to commercially license a small number of producers that could be tightly regulated, carefully overseen and that was what was going to get rid of the riff raff in his view.

I was in tech, and my co-founder, Billy Levy, also was in tech, and we saw this is just a really interesting cultural moment, entrepreneurial opportunity and what the government really liked about us when we started talking to them was we knew nothing about cannabis, and we had no experience with cannabis, and in their view, if our business failed we’d go back to tech and we wouldn’t have the connections to put it in the streets.

Tim Seymour:                    Is that critical for anybody coming into the industry at that time? Was that the blueprint for, “I’ve never done this before and actually I’m a novice.”

Peter Miller:                       Largely speaking yes. There was a little lip service paid to a few people that were the absolute most proper participants of the old systems. There were a couple people, but really it was lawyers and bankers and tech people. People that had no experience, which was somewhat counterintuitive, but hugely beneficial to us. We applied. Successfully won a license in those early days, and that allowed us to draw early capital. We found another group that was also early licensed and merged entities and formed a company called Mettrum Health Corp. five years ago almost today. Time flies incredibly quickly. A few months after that, Fidelity led a financing to go public. It was the second company to go public in this space to Tweed before it was called Canopy Growth.

Tim Seymour:                    What was Fidelity thinking? I mean seriously. They had a lot on the line for reputation. When I think of Fidelity, I think of one of the more conservative financial institutions in the world. This doesn’t make sense to me.

Peter Miller:                       Yeah, and I think we might have been their first and last check to the space, mostly because it was an underperforming investment for a couple of years, but I think what they saw was that our team was a bunch of bankers, lawyers and tech entrepreneurs. Our chairman was the former CEO of TD Dominion Securities. Another one of our board members was the commissions of the RCMP. That would be like the head of the FBI here, and he’d just left his position as the head of Interpol, so we had a super cop, the banker, a bunch of tech kids who wouldn’t hurt a fly, and then we had an auditor on our board and it just read like the exact opposite of who you’d pull at a central casting for a weed business. That was like a lot of the folks. Bruce and Mark and the folks at Canopy. Similar profile.

Tim Seymour:                    Talk about how Canopy become essentially a partner, and ultimately your sugar daddy, but again, it’s a small community. Certainly back then it was even smaller. How did they view you, and ultimately for people that don’t know the transaction, what was the strategic element of this for them?

Peter Miller:                       By 2015, Justin Trudeau became Prime Minister of Canada at the very end, and that was really the catalyst.

Tim Seymour:                    By the way, Bruce is Bruce Linton, CEO of Canopy Growth. I don’t mean to be pedantic, but he is like Bono or Madonna, or Sting. They go with their first name.

Peter Miller:                       He’ll go down in history when they’re writing the book on legalization. He’ll be like the less controversial Joseph Kennedy, Sr. kind of guy who really was there at the beginning and jumped on the commercial opportunity post prohibition.

Once Justin Trudeau won there was this sense that legalization may actually take place. We went from trading 1,000 shares a day at $1.50 and no one caring, to all of a sudden a bunch of volume. The stock went for a run, and the first wave of MNA started taking place. It was a small world. It still is a small world generally, but in cannabis it’s extremely small. I think we’ve been good about not trashing anybody, because you never, you’re going to wind up being partnered with, bought by, pairing.

Tim Seymour:                    How would you trash them?

Peter Miller:                       It happens.

Tim Seymour:                    It’s interesting, and not to get lost on this, but in some sense, some of the Canadian LPs that have been the most successful have been the biggest targets just because their market cap has exceeded necessarily what people perceived to be a valuation that makes sense, but some of the biggest players in Canada, in some sense they take a lot of heat for having been pioneers and being very successful in capital markets even when their businesses haven’t been as mature.

Peter Miller:                       It’s a tricky situation and since Canada’s a federally legal environment it was able to attract certain capital that didn’t have to be worried about the whole state federal issue, so Canada punched above its weight capital markets wise, because there was a time, going back to our transaction, we competed. We were fierce, but respectful competitors, and as we were looking at the space, ultimately conversation led to, “This is a powerful combination.” We had a similar number of shares outstanding and the transaction was .8 to one share ratio, so it almost cut Canopy in half. All stock. People said we were crazy. People said they were crazy for paying $430 million, but anyone who held on-

Tim Seymour:                    Big transaction.

Peter Miller:                       That would be a couple billion more. More than a few billion today, because that was an $8-ish.

Tim Seymour:                    Where were you after this transaction, because again, you had built your company, and yet one of the great companies in cannabis history takes you out. What was either your role in the new entity, or how did you take what had obviously been an enormous success and really how do we get to SLANG, which ultimately is also the combination of bringing a couple assets together, which we’ll talk about.

Peter Miller:                       The early days of Mettrum Health Corp. was my bootcamp operationally in the space, and that took us to the US quite a bit for recon. Visiting Colorado, especially in the early days you got a sense that Canada, while it was ahead on legalization and the capital markets had a lot to learn operationally and brands wise. We saw products go from an unbranded jar of cannabis with the little label maker saying, “Super Lemon Haze” to vaporizers, to edibles, to more sophisticated things. We already knew that was coming. The interest for me was to be part of that.

After the Canopy transaction on a very friendly basis, Billy and I decided to focus our efforts on the US. Making investments personally. Continuing to foster relationships that we’d formed years earlier and put all of our weight behind the next wave, which we saw as consumer packaged goods. We got our 10,000 hours in that limited license vertically integrated environment, which was great, but really hard to scale, and it’s really hard to be a great farmer, a great processor, a great formulator of finished goods. Great marketer, great retailer. Usually people consolidate to that later, and sometimes they break stuff off as we’ve seen in other industries.

Our view is this is going CPG. We want to be part of it. That was an early idea two and change years ago, but we jumped on that and Canopy liked the concept, but they couldn’t put equity into the business so we created a unique structure that allowed them to have a warrant to buy equity if the federal law-

Tim Seymour:                    Changed.

Peter Miller:                       Allowed them to do so.

Tim Seymour:                    Sounds like something we’ve heard of recently. A transaction.

Peter Miller:                       Which was affecting the template for what happened-

Tim Seymour:                    With Acreage.

Peter Miller:                       With Acreage. Other LPs have quietly done similar things, or they’ve spun out assets with convertible warrant structures. That was early. We were proud to be part of that, and ultimately the following two years led to putting together the assets, the people that were the best of the things we saw and the people we knew, so as SLANG went public this January, and we were incredibly lucky that we were one of the few deals that went way above and stayed above issue, decent volume. The trends have come in our direction. It’s not like any genius on our part, it’s just timings worked really well.

Tim Seymour:                    This is happening at a time when obviously if you think about the fourth quarter of 2018, you had all the major US multi-states coming to market. They were RTO’ing, by the way. You decided to IPO. I mean talk about that.

Peter Miller:                       Yeah. Most people did an RTO in Canada, where they backed into a shell, or a CPC. We did a full prospectus, and that, I think inspired a lot of confidence in the more institutional investment world, and when we were raising money, especially in New York, there was a certain reticence to be part of a traditional Canadian cannabis RTO, and people were really appreciative of the fact we did a prospectus, which was a little more work at the beginning. A lot more disclosure, but cleaner and I think was part of why it was a successful [crosstalk 00:11:45].

Tim Seymour:                    Yeah, I mean if you think about that, I mean almost every one of those multi-state operators that RTO’d in the fall, not only was there a market decline. That was an exogenous factor to cannabis, which certainly impacted cannabis, but it clearly was a case where the RTO was becoming a bit of a stigma.

Peter Miller:                       Yeah, there were a few black eyes that the Canadian markets got from different reports of transactions that went down, or a couple years earlier, and just less transparency makes people less comfortable. I think that there were a lot of issues in the fall. There were macro things that affected those folks beyond their control. We waited that out and I think over the long, long term none of that will matter too much because the people putting a fundamentally good business together will be successful, but it doesn’t change the fact that on the days the stock is up I get no calls, and the days the stock goes down I get a thousand calls. I’d rather have more days when it’s up than down operationally.

Tim Seymour:                    Well, all I can tell you is the S&P’s down 130 basis points right now, so I’m sure cannabis is down four.

Peter Miller:                       Yeah, and eventually I think you’ll see maybe things go the other way because in CPG where we believe this all goes, Haagen-Dazs will do quite well relative to the lower quality ice cream, because it’s one of the last micro luxuries you get. If times are tough a $10 pint makes you feel pretty good for the little bit of time that you’re eating it in front of Netflix.

Tim Seymour:                    Indeed.

Peter Miller:                       I think cannabis isn’t going to be bulletproof in a recession, and certainly the capital markets and the fundamental business will obviously move in sometimes different directions. The long term they’ll catch up to one another, but I do think that we are all lucky to be their investors or participants or thinking about either one of those things in an industry that does have so many macro tailwinds globally.

Tim Seymour:                    I want to get to the capital markets world because I think there’s no question that a big part of the evolution of the industry has been the capital markets dynamics for better or worse. Let’s get to that. Ultimately I want to get down to the essence of SLANG and how you view yourself and in a world where you’ve created companies, you’ve certainly focused on consumer products, but you’ve been referred to as the conglomerate of weed, or a portfolio of brands. How do you think of yourself? For a company that really has some brands that you brought together right away, and maybe you start with the genesis of essentially the Organa acquisition and Firefly, and bringing together well-known brands, and saying, “That we want to add on expertise to and take it to the next level.”

Peter Miller:                       Yeah, we do have a portfolio of brands. As a collection they’ve done almost a few hundred million dollars worth of sales at the cash register. I differentiate cash register because ultimately that’s where you can tell how consumers are voting with their dollars, and that’s how you know where you stand. How we break out geographically, well we do have one product or another on the THC side in 12 states, and a hardware in all the states and a handful of countries. We do generate more of our business west of the Mississippi where it is more competitive, with Colorado and California being the biggest contributors, but also the biggest contributors just tracking the biggest markets for cannabis.

As a consumer packaged goods company, we’ve organized ourselves as such. We don’t own any cultivation. We buy biomass and we process it into finished goods under our brands and our formulations, and we don’t own any retail either. Not because we think it’s a bad business-

Tim Seymour:                    I’m guessing some of your partners, your strategic-

Peter Miller:                       Yeah, retailers are our partners so we’d be competing. What you see typically in the grocery business, or most retail is that chain stores aren’t carrying other chain stores private label brands. Your house brands aren’t going to carried by your competition, and so by not owning retail we’re in almost a few thousand retailer environments and the success of those retailers is our success and vice versa. We’re not cultivators, we’re not retailers. We’re really focused on procuring biomass, making our finished goods, and then wholesaling it and distributing it to end retailers, and that’s a model that we’re able to operate under because most of our business is in those more mature markets.

In a limited license, early stage market, you just can’t do that because they require vertical integration because that’s easier to regulate. Going back to Canada, it was a lot easier to say, “Okay, five people are licensed and you each do everything from seed to sale, so I can send three government officials to your facility every month, which was insane, but that’s what they did, and we can go through everything much more easily than if there were 1,000 of you.

But once the stigma goes away, people realize the sky isn’t falling. The data comes in. Car accidents are flat. Opiate deaths are down. Most importantly tax revenue is up and they say, “Oh man. How do we get more tax revenue?” Well the way you get more tax revenue is license more people, break up the verticals and generally create a bigger industry and that becomes the phase where our business model really excels, but even in those limited markets, which you can’t ignore because they’re incredibly exciting, like Illinois is going to be hugely exciting with the new regulation that was announced. We look for partnership. We’re not elbows out. We don’t think that we’re the smartest and we’re the only ones that are going to be able to pull this off. We look for good partners, and a good example of that is in Florida, where we said, “This is too exciting of a market to ignore.” Florida, on top of the fact that it is a large population, the data is showing us they’re big cannabis consumers, and that’s a limited license vertically integrated environment.

We had a lot of conversations and ultimately the largest retailer selling the most cannabis in the state was the company we ultimately decided to work with. They’re called Trulieve and the way we looked at the Florida market was we could either buy-in or earn-in. Buying-in is obvious. You buy a license or you buy a company that has a license, and we saw earning-in as saying, “Hey company X our brands, we can demonstrate, will bring people off the street into your stores versus the other stores. You can look at Harvard bus-

Tim Seymour:                    How do you decide on a Trulieve? What was it? I mean clearly they are market leader. They’re one or two in every segment, but as you assess again an earn-in, it’s critical that you choose the right partner. What was it about Trulieve as opposed to Vitacan or somebody else in Florida. What did you see?

Peter Miller:                       To put it really simply Trulieve sells the most weed. That makes them by far the most appealing person to us because that’s our goal as well. Also, Kim Rivers the CEO is an incredibly smart person and really good operator, and just runs that operation incredibly well.

Tim Seymour:                    At this point, because of the nature of the operators, do you have a wishlist of where else you guys think you want to be finding these partners, and again, partner in the truest sense of the word. Kim is somebody that stands out for people to know Trulieve. I mean it’s a very well run company. It’s a company that’s been generating higher margins. Got out of the gates early. Tell me how you asset partnerships? In the places you are not yet, what are you looking for?

Peter Miller:                       On top of the metric I just gave, you also have to look for people that are practical and thinking further into the future about how we can help each other. We were talking in the green room with the CEO of a multi-state operator, but how it is a big pie and there are going to be a lot of opportunities to win, and there’s no business model that I can say definitively is the business model for the short to midterm. We can see in the distance how this probably breaks down and we can apply margins and basic metrics from other industry to cannabis, but at what point is that going to be the case.

We look for people that are practical. In terms of the wish list, this is obviously one of the places that’ll be really exciting.

Speaker 3:                           How about Illinois?

Tim Seymour:                    Absolutely.

Peter Miller:                       Illinois is going to be a great market, but again, it already is if you’re in the black market. You can look at human behavior. It tracks pretty consistently in the western world. Even though reported cannabis use isn’t always as honest like Vermont to Alabama, but I bet if you test the sewers of all of these cities, the THC content in the aggregate urine per capita is super similar.

Tim Seymour:                    I don’t want to be doing that.

Peter Miller:                       I’m sure you have analysts for that.

Tim Seymour:                    You’ve gone out of your way to talk about SLANG as being a CPG story, and I’m sure everybody whose in this room has heard cannabis industry being described as, “It’s about brands. Brands matter.” Good, because that’s a second derivative conversation that I think we were not having even 12 months ago. People understand pricing power comes with brands, sophistication comes with brands. That truly that’s how you stand out, but I want third derivative. Peter, how do you compete where everyone who I talk to says, “We’re building the brand.” How are you endeavoring to stand out from the crowd? It just so happens you’ve got some core hardware and house brands that I think have become staples of the industry, and therefore they’re out there, but I hear everybody talking about brands all the time and that’s great because that’s what it’s about, but I want to hear how you’re going to compete with all the other guys that are saying it’s about brands.

Peter Miller:                       Yeah, I think there’s going to be a certain special sauce, but a lot of it is just the textbook CPG playbook. The head of our sales organization came from Konica Minolta where he was selling the most boring product in the world, the office printer and photocopier. Now in cannabis he’s been unleashed to sell something that people actually want, but he still applies the same sales methodologies. He’s organized his sales team in a similar way and I think you’re going to see better and better bench strength coming from the mainstream into cannabis as the stigma comes down. But, the brand also has to stand for something and be associated with something. If you think about the original brand as the hot iron you’d poke your livestock with. It was just to say, “This is my livestock. This is my product.” There’s a lot of people with brand, but nothing to poke it with.

Our brands have been in market for a long time, so part of it, another thing our head of sales likes to say is the best ability is availability. If your brand is in a lot of places, that’s how you create subconscious relationships with people. I’ve seen that before. I’ve seen it in all of these places. I’m trusting it a bit more. They develop then a relationship of purchasing it. Then they form habits. The first few trips into a dispensary starts very conversational. You might be in there for 15 minutes talking to a bud tender, but by the 100th time you know what you want, everyone’s busy. They just want to come and go, so I think just availability is super important.

But then brands typically do have to stand for something or be associated with something. Nike isn’t just a swoosh. That’s how you tell a Nike, but they did reinvent the sneaker in the 70s.

Tim Seymour:                    Innovation. I had those Air Jordan’s that you could pump up the back and they still had me jump about an inch off the ground, but nonetheless.

Peter Miller:                       Hermes is coming off of 200 years of craftsmanship. It’s not just an orange bag.

Tim Seymour:                    What is your ethos? What do people know about SLANG?

Peter Miller:                       Our 510 thread to be technical, but our cannabis vape is one of the first-

Tim Seymour:                    Explain the 510 thread for those that don’t understand the literal linkage here.

Peter Miller:                       510 is just a diameter in millimeters of the threads that you spin the cartridge onto the battery, but it’s the generic. It’s the USB standard thing for vaporizers. Lots of people have it. It’s almost an agreed upon form factor. We were the first in market with one of those a lot of years ago. It’s become very competitive, but our brand is based on both innovating in that space and then competing successfully in that space.

In March, we still had the number one selling 510 thread vape in Colorado after facing over 150 competitors that have come and gone over the past seven years on that product. Then on the Firefly side of things, we just are launching a new dry herb vape, but we were one of the first with a convection drier vaporizer, which I can get into a lot of technical mumbo jumbo, but basically it just allows you to capture a lot more of the flavors, a lot more of the cannabinoids. It’s more of a connoisseur product, which again, prices it higher than most people are interested in paying, but it’s based on innovating in that space, and it authentically delivers value to someone in the market that wants that.

We have products that have history. We have products that are differentiated. Debra has a report on the vape space, which you can look at.

Tim Seymour:                    That’s a fascinating report, by the way, which, if you didn’t know what 510 was before, you’re going to know what 511, 512 … I’m kidding, but the bottom line is, it’s become … First of all, I mean it’s a very competitive segment. You’re competing with not only Pax, but you’re competing with the entire content of China. You’re competing with … I see deal flow all the time, and half of them seem to have a vape element to what they’re doing.

Peter Miller:                       I mean on the supply chain we leverage China. We’re not saying that the 510 cartridge that it actually goes into, that’s a piece of hardware we’ll buy from a third party. What’s inside it matters. If we all agreed that this is the size of a beer can, you’re no longer competing on who has the cheapest, best can. It’s more about what’s in the can and how you describe the relationship people have with what’s in the can. That’s how I see the 510 thread side of things going.

Then with Pax and the proprietary battery and cartridge model, there’s a bit more of a technology angel there, but we’re starting to see, even with the proprietary stuff, Pax and everybody else, the sales are basically equal to the high end formulations of the 510 category. It’s going to be very competitive, but what we like, and a better model is that we’ve been competing.

If you go, again, to Colorado, Oregon, California, Washington, all these places. It’s highly competitive, so when we’re looking at acquisitions, we really like management teams that have succeeded in those markets, because they’re like athletes that have trained at altitude. You bring them down to sea level and they have that extra edge because they’ve been just duking it out. Not to say that-

Tim Seymour:                    A vape, or a cartridge that’s been particularly successful in California, which is the most competitive market. It’s the largest market in the world. That’s the guy you want.

Peter Miller:                       Yeah, from a management standpoint, and I think we’re all witnessing a shift in brand trends from the giant monolithic top down brands like Craft and whatnot, to the more regional plays. Just generally speaking, and it’ll happen with cannabis too. There’s a certain regionality that people are drawn to and so, even if you have a 510 thread vape in Colorado that’s really popular, it doesn’t mean it’s automatically going to be welcomed by the Washington market, or the Oregon market. Especially the Oregon market who really does care about the local craft story at a good price. That’s why in our portfolio we’ll have products that technically have similar characteristics in Colorado and Washington, but they address totally different markets, and we don’t see them as overlap and they’re both doing incredibly well.

Tim Seymour:                    Not only are we talking about geographic, but we’re certainly talking about consumer demographic targets too right? We’re talking about different price points, and I do want to hear about the Firefly 2 Plus because that’s a Rolls Royce that’s rolling off the assembly line soon. Talk about that. I mean you’re addressing different demographics, and yes, the consumer in Colorado is different than the consumer in Illinois. How do you view that?

Peter Miller:                       The vape category now segments pretty clearly because it’s mature enough that you’re starting to see these trends. When any of these-

Tim Seymour:                    In the Green Market on page … It’s very interesting.

Peter Miller:                       Exactly. Since it does become, at maturity, almost as big as bud, and it’s hard to say at maturity, but today, if you looked at last year in California, flower made up about 40% of the market, pre-rolls were 8% of that, and so you’re seeing a 32% pure flower that you grind up, roll up and smoke, or put in a bowl and smoke, or cook into food. Whatever the case may be, that’s flower. Then if you looked at vape it was around 30%. Almost neck and neck, and so what you’re seeing in-

Tim Seymour:                    And growing at a faster rate.

Peter Miller:                       Growing quickly-

Tim Seymour:                    Figuring that’s 40s.

Peter Miller:                       It might be the dominant sector, and it’s segmented a few ways. You actually see premium priced vaporizers, both on the oil side and on the hardware side. You see the discount stuff. You see the value stuff in the middle. You see specialty and we address all of those markets. The Firefly on the dry herb side is a Rolls Royce. It’s not going to appeal to everybody, but the same people that … Like my father-in-law will buy a bottle of wine, he’ll tell us about it for an hour, and then he’ll pour it through a crazy system of God knows what. There’s a bunch of hissing sounds, and out of the bottom he spins it. He really cares and knows what he’s talking about in that way, but a lot of people I know buy boxes of wine and pour it into a Dixie cup and it’s just a different buying pattern. In vape, the Firefly is definitely catering more to this crowd.

Tim Seymour:                    I’m guessing this group of people care about the Firefly too and a dynamically heated with every inhale in a titanium shell. This is the kind of stuff that I think people are paying attention to.

Peter Miller:                       There’s better mousetrap components to it. The temperature curve does align to capture all the cannabinoids along the spectrum because it’s not just THC, and as the market evolves and people get more sophisticated. Now the CBD gets a lot of attention, it’s a dominant cannabinoid next to THC. Totally different effects. Symbiotic in a lot of ways, but there’s other cannabinoids as well, and they all decarboxylate at different temperatures, and having a temperature ramp that allows you to capture them all, as well as the turpines that provide the flavors, which also have a lot to do with the effect, the volatilize at different temperatures, so a product like the Firefly 2 Plus helps you really get that full connoisseur experience. We’re also extending that brand-

Tim Seymour:                    Who else is doing that? I mean this sounds to me, especially again, and the technology behind truly heating the product to the level that truly brings out the optimal impact. First of all, how are you testing for that, and ultimately how long did it take for that product to come off the assembly line?

Peter Miller:                       The product was developed by a guy who left Apple to start Firefly a handful of years ago, and while he will often bring up the value of the stock options he left behind leaving Apple 10 years ago, he did create a beautiful and highly technically capable product, and not a lot of people have created these convection dry herb vapes because of that complexity, and because the consumer that uses it has to be a bit more sophisticated. There’s a lot more competition in dry herb vape on the conduction side, where it heats more like an oven for a couple minutes, and then you inhale. Pax does an incredibly good job with that. There’s a handful of others. As the dry herb category maxes out, I think you’ll see that not flatten, but you’ll have your market. Rolls Royce isn’t selling a million cars a year.

Then, if you go down the exact opposite end of the spectrum, more to the distillate side of things, we have a product that’s growing like gangbusters in California, but a lot of that just has to do with the fact that our supply chain is tight and we’re able to pull the price lever and convenience for people. A company that did that extremely well, better than anybody was just acquired by CuraLeaf last week called Select. A distillate based product. They just did an amazing sales job, organized their supply chain well, pounded pavement, were incredibly aggressive on pricing. Would nearly consign product, and built an awesome market share.

Tim Seymour:                    A lot of people, when you start hearing about the technology behind the vaporizer, I think people also mistakenly believe that this is a place that the tobacco company will come in and that there’s some transference between an e-cigarette and essentially vaping, especially a dry vaporizer. Break that down. Talk about why you’re not terribly concerned about Jewel or anybody else that seems to dominate in the tobacco world right now.

Peter Miller:                       The important thing you hit on is that the early cannabis vaporizers were just repurposed e-cigarettes, so they all ramped to 600 degrees, which would be optimum for nicotine, but not so much for THC. You’ll capture all the cannabinoids by 422 degrees, which is funny, but it’s not 420.

Tim Seymour:                    Not 420.

Peter Miller:                       We would have set the temperature to that, it would have been funny marketing, but we wouldn’t have had as high quality a product. The purpose built cannabis vapes, there aren’t many of them. With big tobacco, they’ve placed their bets. Altria made a big investment in Cronos, another Canadian licensed producer from early on that went through a few ownership groups, but now is Altria’s bet. Pax has a certain DNA from when they were Pax Labs before they spun off to be Jewel and then Pax Labs, and I think it’s just a fundamentally different experience and use case. Tobacco versus cannabis. The only similarity is that the dominant way to consume historically has been historically, but that’s pretty much where it ends. Totally different effects, both positive and negative, although I shouldn’t say there’s any positive, but I mean there is scientific arguments for nicotine in a well rounded-

Tim Seymour:                    Yeah, but typically people go out to consume an entire cigarette, whereas, the ideal dynamic, or at least part of what the dry vaporizer is solving, and solving from a efficiency of use of product, by the way, some very expensive products that you don’t want to really burn through too fast, but sometimes people puff and wait, and puff and wait and come back in 20 minutes, and you don’t smoke a cigarette like that.

Peter Miller:                       No, exactly. It’s more social in some ways. It’s also more personal in a lot of ways, and yeah with the Firefly Mini, not to keep hawking it, but I will because that’s my job.

Tim Seymour:                    Why not.

Peter Miller:                       It does lend itself to that stop and go. It heats up in a few seconds. You take your puff. You put it down. Hasn’t destroyed the product because it hasn’t heated it up like an oven, and so that is certainly a use case that’s different tobacco to cannabis.

I think what we’re seeing broadly speaking is big alcohol saw cannabis as a threat. We’ve talked to everybody you can imagine, and some of them are more candid than others about how they’ve been talking about cannabis in board meetings for over a decade. They still don’t know exactly what their move is, but the dust cloud on the horizon is now like a stampede you can see coming right at you, so a lot of people are trying to figure out where they should stand, so you’ve seen some big alcohol partnerships with cannabis. You’ve only really seen the one big tobacco partnership.

You’re seeing some pharma stuff. If you looked at what cannabis generally could address, whether it’s CBS, whether it’s THC, whether its other cannabinoids, you’re addressing a multi hundred billion rec market. You’re addressing a multi hundred billion sleep market. A multi hundred billion pain market. The list goes on. That just also goes back to the opportunity sides for all of us and how it’s not going to be like ride sharing where there’s only two apps I want on my phone, or social media or search. It is a far more open market to more participants, more opportunities to win and this whole cannabis fad isn’t going to blow over. They’ve been using it for thousands of years. It’ll be used for thousands of years into the future, and there’s this market opportunity that’s taken place due to regulatory shifts, but I don’t see that ending either for a long time because at some place in the world, they’re still going to be very strict on cannabis for a long time. It’s hard to go from beheading people for it to full legalization overnight. We’re coming off a much less aggressive position in America, but still it hasn’t happened overnight. I’m sure my parents, and their friends were talking about how cannabis was going to be legal any day now in the 50s and 60s and that didn’t play out for a long time.

Tim Seymour:                    It’s funny you bring up the rest of the world. Why don’t we just go there real quick. It was going to be part of my fast fire.  Let’s do a little fast fire. This is where I just want to ask Peter a phrase or something, and Peter’s going to quickly give me his first thing that pops to mind. Doesn’t have to be one word. It can be anything, but most interesting country in the world outside of North America for cannabis right now?

Peter Miller:                       I mean if Mexico doesn’t count, I would say that they are talking broad legalization, which is interesting. I think western Europe is going to play out a lot like the US, but since the EU can move a little more quickly together it will do so. Germany has been interesting already for us, so I think western Europe’s hard to pick down. Germany’s probably the most interesting today.

Tim Seymour:                    Acreage Canopy deal. Your thoughts.

Peter Miller:                       I think it was great for the sector to see Canadians using their paper, using their position to make bets on the US. I think it’s currently facing a little bit of a tussle with the fund that came out against the deal. I think we’ll see the confidence level people have in the deal in terms of how closely the stocks trade to the deal price. Right now it doesn’t seem like the confidence is huge, but I think it gets done, and I think it’s going to be great for everybody.

Tim Seymour:                    Who’s your cannabis idol?

Peter Miller:                       It’s incredibly tough. There’s capital markets people that have paved the way massively like Bruce. There’s people that have paved the way in the culture that have taken a lot of risks. Even the people that some people like to make fun of, like the Tommy Chong’s and the Cheech and Chong jokes and the list goes on, but I think the DeAngelo brothers at Harborside did a huge job for the industry period, never backing down, so it would be incredibly hard to pick. But the celebrity, the capital markets, the activist crowd have all done their piece.

Tim Seymour:                    States act. State banking? Time? Any way you want? When you hear that, what does that mean to you?

Peter Miller:                       I think State’s Act means liquidity to me. The banks get comfortable. The exchanges get comfortable. The institutions get comfortable and then there’s a ton of liquidity in the space that isn’t there today.

Tim Seymour:                    Put your investor hat on, one of those folks, because we know where you sit, but public or private right now? Where should people be?

Peter Miller:                       Depends what your time horizons are and what your risk tolerance is. You can invest in a public O through financings that come out every few months, usually at a discount to the price, and with some of the bigger names you can hedge it, and so if you’re faster money you obviously have a lot of options in the capital markets. If you have a longer term view there’s some interesting privates you can play as well.

Tim Seymour:                    Difficult question, as you sit as a CEO, but single state or multi state operator? What’s the best model?

Peter Miller:                       For us, we were the original multi state in a lot of ways because we’ve had products in multiple states, and depending how you define operations, operations in multiple states. I think what people usually talk about is they talk about vertically integrated limited license, and they say MSO, and then there’s the competitive states. We personally prefer the competitive states for a lot of reasons, some of which I got into.

As an investor though, I think the MSOs represent a good momentum trade because people have muscle memory, and the Canadian trade was so rich when it was limited license vertically integrated and you saw Canopy go from 89 cents to $70, and it has a much more similar business model to a Cresco. I’m not going to give you stock ideas, but I think you can’t go wrong with MSOs.

Tim Seymour:                    I agree. I agree. Next big strategic in the sector? Who’s going to splash in? Whether it’s a Constellation style that may never be done again in terms of the relative size to the industry, or to the players itself, but whose next? Hazard a guess?

Peter Miller:                       I think it’s going to be one of the non alcohol CPGs. I’m not sure which, but Buffett was bobbing off at his conference last week about how it would be a mistake for Coca-Cola to get involved in cannabis, although they actually bought a company that had CBD water a couple of years ago, so obviously not too deep in the weeds of his investments, but I think it’ll be someone more like that then it will be another big alcohol company.

Tim Seymour:                    Coca-Cola not close? I’m asking?

Peter Miller:                       Yeah, they bought a company. I think it was called Dirty Lemon, or something, and they had CBD in the product. They removed the CBD. This was pre-pharm bill. I’m not sure if they put it back in. They’ve dabbled. I think Unilever is going … I’m not going to tell tales out of school. I think there’s going to be a lot of people doing things in CBD initially. Already there have been announcements. I think it’ll be a big CPG player that is non alcohol.

Tim Seymour:                    Somewhat related THC infused beverages as a market segment. Exciting?

Peter Miller:                       THC infused beverages get a ton of attention. I think CBD infused beverages might be a bigger opportunity near term. I can say the reality of the situation is, and this is someone who has a beveraging market, is that in California, it was 0.8% of the market last year. It’s never more than a percent of any mature states market, but it’s getting a lot of attention. Huge investment, and there’s a bit of a gap between the reality and the possibility. We have to let data decide what we’re going to put resources behind. Vape and edibles represent more than half of the entire industry, so that gets half at least of our attention.

Tim Seymour:                    Constellation isn’t in this to suddenly be the Corona of THC beverages?

Peter Miller:                       I don’t think so. I think Corona and a lot of these folks are in the lifestyle business. The mood enhancement business, and if someone’s on the beach with a Corona and a joint, they want a piece of the action in both hands. They’re not going to make you put the joint in the Corona and shake it around and drink it back. That’s gross. I mean it’s a decent ashtray when you’re done.

Tim Seymour:                    Probably been done actually.

Peter Miller:                       Probably. Yeah, someone whose had a few too many of both, but I think that the big alcohol companies probably see this as, “Yeah, it doesn’t have to be the round peg in the square hole.” They’ll go where the market goes. The data will guide you and you can’t force things into existence the market doesn’t want. Hopefully they want it though eventually.

Tim Seymour:                    We’ll end with this. The future? The future for SLANG? The future for the industry? It’s not a one word answer so I’ll give you a second.

Peter Miller:                       Yeah, I mean the future at the highest level is that people will be consuming more cannabis in the future than in the past as long as there isn’t some massive population like Malthusian check, but I think cannabis consumption is going to continue. Legalization I expect will continue also for so many reasons from tax revenue to social justice, all the way down.

I think in the actual business environment, the models will shift more to the real world economics. You’ll see more of the CPG focused guys, the retail focused people, the cultivators and all of those verticals will be compelling to different investors for different reasons. I think for SLANG, we’re going to continue running our playbook as a branded product focused company. You’ll see us making more acquisitions to develop the portfolio with a regional focus, as well as a category focus, and I think that for all of these companies that do a good job regardless of any market ups and downs, they’ll be very successful.

Cannabis gets compared to tech sometimes. There’s obviously some major differences, but in the sense that they were both big waves that took place, you saw Amazon start before the dot com crash and live through it and be one of the most successful companies in the world. There’ll be cannabis companies that fail. There’ll be more that fail than succeed. People talk about the green rush. They don’t talk about the green flush where most of these companies aren’t here, but the good ones will be, and they’ll be bigger and better, and if you’re in this industry, you’re incredibly lucky to be part of an industry that has this secular trend of growth. If you’re just a cannabis consumer, you’re incredibly lucky that you’re not going to have your life ruined by a small arrest and conviction for possession, and you’ll just have an availability of more product generally. I hope we see destigmitization. The market will expand. That’s my crystal ball.

Tim Seymour:                    Great. Future sounds bright. Peter Miller and SLANG Worldwide. Thank you very much.

Peter Miller:                       Thank you. Appreciate it.

Video StaffMarch 5, 2019


Recorded at the Accelerate Cannabis event in Newark NJ.

Debra Borchardt, Editor, GMR

Slang and Organa Brands just recently did a merger/acquisition. How is it?

Chris Driessen, President, Organa Brands

Oh, it’s been great. It’s been great. It’s been an absolute dream come true. So Slang acquired Organa Brands, so now we’re part of Slang, and it’s been awesome. Our partners, Billy Levy and Peter Miller are great capital markets guys, a lot of experience coming out of Canada, plugged in with us, obviously on the cannabis distribution side, and so far it’s been a match made in heaven.

Borchardt: Now, Organa was already killing it. You guys did over $100 million in sales since 2014, so already a really strong company. What is Slang going to do for you at this point?

Driessen: You know, the ultimate reason we decided to go public and move forward with the transaction, when you looked at what was happening in Canada, and the multiples on these businesses, we really had an honest conversation between myself and my partners to say, “Gosh, we could run the best cannabis business in the world, and you’re just not going to be able to keep up with what’s happening in the public markets.” It was also something that gave us a lot of trepidation, because it’s something we knew little, if nothing, about. So we wanted to identify who was likely going to give us the best opportunity at success in that world. We were very confident, obviously, in what we do, and getting merged up with the partners we did, and Peter and Billy, as I said, it’s just been … it’s been great. It just allowed us really to capitalize yourself to execute on a strategic growth plan and continue expanding our empire.

Borchardt: And, you just signed a deal with Trulieve which is going to get you guys into Florida. So, this seems like a really great combination, because Trulieve already their flag planted in Florida, and you guys have the product, so …

Driessen: Yeah. They are the 800-pound gorilla in the room in Florida. They have, according to the Department of Health, a 60+% market share. And as you know, we go and we really do a lot of due diligence in vetting on our partners when we want to enter into a relationship, and over time it was just clear that their culture, their vision for the Florida market, the infrastructure, just the passion they share for bringing products to the patients in Florida really aligned with what we were trying to create. So it just seemed like a great fit, and over time I think that’s going to bear itself out.

Borchardt: So, do you have any new products on the pipeline, for Organa?

Driessen: We do. We’ve got a lot of fun stuff lined up for this year. One of the newest things that we’re going to be releasing is actually the week after next is the new reiteration of our reserve line. It’s a botanical and terpene-based value-based cartridge. Craft Reserve does great cannabis-derived dominant market share in pretty much every market we’re in. What we’ve identified is that there’s a huge section of the population out there that, you know, wants a quality product at a great price. So being able to provide that to patients and consumers everywhere is something we hold near and dear to us, and I feel really good about it. It’s a winner of a product.

Borchardt: Absolutely. With taxation so high in so many places, it’s really important for the cannabis companies to recognize that for the consumers that are already going to have to have this added expense on top of their purchase.

Driessen: Yeah, no doubt about it. We spend a lot of time segmenting out our products into different tiers, and then obviously doing different pricing segmentation within those tiers. But it’s all about the business of how do I match you up with the best product for what your individual situation is, and we do a pretty good job of that.

Borchardt: Alright, well, I’m excited. I can’t wait to see this new reserve product.

Debra BorchardtFebruary 19, 2019


Fresh off its successful IPO, SLANG Worldwide (CNSX: SLNG) has formed a strategic partnership with Florida-based Trulieve Cannabis (OTC: TCNNF) to offer cannabis patients in Florida access to leading cannabis brands in Trulieve’s dispensaries across the state. As part of the agreement, Trulieve will have an exclusive license to SLANG’s extensive portfolio through its U.S. subsidiary, National Concessions Group, Inc. better known as Organa Brands.

Florida is quickly establishing itself as a significant cannabis market in the U.S.  The state has registered over 180,000 medical cannabis patients, a number that has tripled since 2017. According to the Florida Department of Health, Trulieve is responsible for consistently producing and distributing between 60% and 80% of cannabis in the state. The company has 24 dispensaries and home delivery available throughout the state.

“Great partnerships and collaboration are foundational to SLANG’s culture, scalability, and growth strategy,” said SLANG’s CEO Peter Miller. “Not only does Trulieve operate one of the most impressive cannabis cultivation and distribution businesses in Florida, they also share SLANG’s commitment to bringing leading cannabis products to consumers. Every year, SLANG products deliver millions of high-quality cannabis experiences to consumers around the world and, in partnership with Trulieve, we look forward to providing those same exceptional cannabis products to Florida’s patients.”

As a result of the partnership, SLANG will introduce the O.penVAPE, Bakked, District Edibles, and Magic Buzz product lines to Florida medical patients. The company said that the availability of edible products will be subject to regulatory approval by the Florida Department of Health. As part of the agreement signed by the two groups, SLANG will collaborate with Trulieve with regard to the production and distribution of the SLANG portfolio of products, offering in-house training to staff in preparation for production and distribution exclusively through Trulieve.

“SLANG operates with the same goals as Trulieve, working to expand patient access and create products that are high-quality, consistent, and reliable,” said Trulieve CEO Kim Rivers. “SLANG’s expansive portfolio ranges from vaporizer cartridges to edibles to concentrates, all products that will provide Florida’s patients with the effective, natural relief they’re seeking in ways that are innovative and fresh.”

According to an Arcview report titled the State of Legal Marijuana Markets, Florida is estimated to have 550,000 legal potential consumers by 2022. It is projected to reach $1.7 billion in legal spending by the year 2022. The report also stated that medical cannabis sales are expected to reach $456 million in 2018, up from $192 million in 2017.



Video StaffFebruary 1, 2019


SLANG Worldwide went public this week using the symbol SLNG and trading on the Canadian Securities Exchange. The shares were priced at $1.50 and jumped 33% on the first day of trading to $1.99. The company is a merger between Slang and Organa Brands, the vape powerhouse that has done over $100 million in sales since 2014. Firefly is also included in the new company.

Organigram Holdings Inc. reported its first fiscal 2019 quarter results with net sales for the three months ending November 30, 2018, of $12.4 million, up 419% from $2.4 million in Q1’2018.  Sales rose 287% sequentially as the impact of legal adult use sales in Canada continues to be felt on the income statement. Net income for the quarter was $29.5 million

Sproutly Canada, Inc. announced financial results for the quarter ending November 30, 2018. The company reported a net loss of C$2.8 million or $0.02 per diluted share for the quarter versus last year’s net loss of C$473,405 for the same time period. In the filing, Sproutly noted that it has not generated any revenues from operations and has incurred losses since inception. The company has an accumulative deficit of $12,312,832

Innovative Properties Inc. d/b/a Nabis Holdings entered into an agreement with Canaccord Genuity Corp. and Eventus Capital Corp. for a brokered private placement of debenture units of up to C$30,000,000.

Dixie Brands Inc.  (CSE: DIXI.U) and Khiron Life Sciences Corp. (OTCQB: KHRNF) have signed a binding letter of intent to establish a 50/50 joint venture to introduce a full line of cannabis-infused products to the Latin American market.

Israel is set to pass a law allowing exports of medicinal cannabis, the Finance Ministry said last week, as the county ramps up its attempt to woo more investment and bolster state coffers. The bill passed its third reading in the Israel parliament in December and is now waiting for the cabinet and Prime Minister Benjamin Netanyahu to sign it into law.


StaffJanuary 28, 2019


“When a brand is so successful that its name becomes ubiquitous with the product (Kleenex / facial tissue), it becomes “Slang” for the product,” said Peter Miller, CEO of SLANG Worldwide. “We are aiming high for our branded products, and their names will be slang for their categories.”

Slang will be going public this week on Tuesday on the Canadian Securities Exchange in an IPO with an implied market value of $541 million using the ticker SLNG. The company was previously known as Fire Cannabis Inc.

Slang is a combination of National Concession Group, better known as Organa Brands and Firefly vape pens. Organa is based in Denver, CO and is best known for its product called O.penVAPE. In addition to the O.penVAPE line, Organa makes the Magic Buzz cannabis beverages, District Edible gummies and a line of dab products called Bakked.

The real key to the company though is Organa Labs, the part of the company that houses its custom extraction process. The company earns royalty payments through its ability to turn other company’s cannabis products into premium vape pens.

Organa’s revenue for the nine months ending September 30, 2018, was $11,699,259  versus last year’s $8,820,455 for the same time period. Total operating expenses for those same nine months was $4.3 million in 2018 versus $4.6 million in 2017. The company reported net income in 2018 of $4.7 million for those nine months. The O.penVAPE brand is the highest selling brand in Colorado with over $170 million in retail revenue generated since 2014.

SLANG is paying upwards of $200 million for Organa, but Billy Levy, the President of Slang said he considered it more of a merger than an acquisition. Levy and Miller decided that the licensed producer side of the business wasn’t a place for big growth in the cannabis industry. They believe that brands and distribution will be the key places for growth. Organa was the way for them to accomplish this goal.

Miller and Levy are very experienced when it comes to LP’s. The two co-founded Mettrum Health, which was acquired by Canopy Growth Corp. (CGC)  for $430 million. Levy co-founded Virgin MEGA with Sir Richard Branson which was acquired by Nike (N). Miller is also the CEO of Agripharm.

As they built Mettrum, Miller and Levy said they came across Organa. The two companies developed a mutual respect for each other ’s businesses. Organa went from selling its products in Colorado to its current count of ten states. Mettrum was sold and Slang became the new plan. “Our goal was to acquire great brands and pair that with distribution,” said Levy. Organa became a founding partner in Slang.

In addition to the Organa acquisition, Slang is also acquiring NWT Holdings, which is also known as Firefly. This is a dry material vape pen that competes with PAX. Miller said he was most impressed with Firefly’s co-founder Mark Williams who was a design manager at Apple leading the Mac OS X interface. “His design expertise is truly blue chip,” said Miller. “We want to leverage his expertise of industrial design across the whole portfolio as well.” He said that the next generation of Firefly vape pens is going to occupy a super-premium segment of the market.  Firefly will also be launching its own oil products this year.

The purchase price for Firefly is $16 million,  50% in cash and 50% through the issuance of approximately 7,450,870 shares issued at a deemed price of $1.50 per share. The company reported $3.1 million in revenue for the nine months ending September 30, 2018, but reported a net loss of $440,000 for that time period.

Slang will also have the right of first refusal to license the Green House Brands, which includes the Green House Seed Co. and Strain Hunters. The Green House Seed Company has produced over 60 award-winning cannabis strains and was founded by Arjam Roskam.  Green House also holds an exclusive master license to Strain Hunters, a series of documentaries centered around the quest for preservation of the cannabis plant, and the series has co-developed documentary series alongside HBO, VICE, and National Geographic.

Following the successful completion of the acquisitions, it is expected that Slang will expand the businesses of Organa and Firefly as a branding and marketing company focused on developing reputable brands and quality hardware products.


Video StaffSeptember 24, 2018


Cannabis is one of the most popular recreational drugs on the planet, and its potentially
wide-ranging medical uses show promise. Given its low rates of addiction and lack of adverse
health outcomes, cannabis has the potential to replace common pharmaceutical treatments
for chronic pain, seizures, insomnia and other conditions that afflict hundreds of millions of
people worldwide. Likewise, cannabis also has the potential to disrupt the alcohol industry
by serving as a substitute for beverages such as wine, beer, and spirits.

Along with the United States and Canada, several countries have followed suit in relaxing
their cannabis laws and allowing for the use of medical cannabis; which in turn paves the
way for a fully regulated and legal recreational market. Several potentially large international
cannabis markets include Germany, Spain, Australia, Israel, and Colombia.

It is difficult to estimate global cannabis prices because cannabis sales usually occur in the
illicit market. Typically, cannabis prices vary depending upon location. Germany has some of
the lowest cannabis prices in the world. Other countries, such as Israel, are starting to see
higher prices as cannabis begins to move into regulated pharmacies.

Due to complex regulations and various international laws, international cannabis supply
chains are fragmented, with only a handful of companies operating internationally. The
largest of these global companies is Canopy Growth Corp., which has a presence in seven
countries along with the United States and Canada.

International Pricing

Due to its status as an illicit or semi-legal substance in much of the world, there has yet to
be a set international commodity price for cannabis. Even in countries like the U.S., where
recreational cannabis is legal in nine states, the price of cannabis can vary significantly by

In Oregon, for example, extreme competition among cultivators has driven down cannabis
prices to roughly $1 per gram. However, in California, a newly open recreational market,
cannabis prices are between $11 and $14 per gram. According to Cannabis Benchmarks,
which tracks the wholesale pricing of cannabis, the national average price of a pound of high-quality
cannabis is approximately $1,285.

Due to federal legalization, cannabis prices in Canada are slightly more consistent. Most
provincial governments are aiming to price cannabis at CAD$10 per gram. On average,
medical cannabis in Canada costs around CAD$8 per gram. However, as legalization goes
into full effect in Canada, prices may fall within the first several years as competition
increases in the cannabis space and as large-scale cannabis production is actualized.

You can read the full report titled “The Economics of International Cannabis Companies” here.

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 10 hours

Super excited to announce we set a date for our Tech Summit. It will be Sept 8, 2022 in San Francisco. Creating the…

@GreenMarketRpt – 11 hours

Medical Mushrooms Leave No Room For the Magic

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.